{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:11Z","timestamp":1790127551039,"version":"4.0.1"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Adjuvant therapy for breast cancer can be associated with decreased bone mineral density (BMD) that may lead to skeletal morbidity. This study examined whether zoledronic acid can prevent bone loss associated with adjuvant endocrine therapy in premenopausal patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> This study is a randomized, open-label, phase III, four-arm trial comparing tamoxifen (20 mg\/d orally) and goserelin (3.6 mg every 28 days subcutaneously) \u00b1 zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg\/d orally) and goserelin \u00b1 zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer. In a BMD subprotocol at three trial centers, patients underwent serial BMD measurements at 0, 6, 12, 24, and 36 months. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Four hundred one patients were included in the BMD subprotocol. Endocrine treatment without zoledronic acid led to significant (P &lt; .001) overall bone loss after 3 years of treatment (BMD, \u221214.4% after 36 months; mean T score reduction, \u22121.4). Overall bone loss was significantly more severe in patients receiving anastrozole\/goserelin (BMD, \u221217.3%; mean T score reduction, \u22122.6) compared with patients receiving tamoxifen\/goserelin (BMD, \u221211.6%; mean T score reduction, \u22121.1). In contrast, BMD remained stable in zoledronic acid\u2013treated patients (P &lt; .0001 compared with endocrine therapy alone). No interactions with age or other risk factors were noted. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Endocrine therapy caused significant bone loss that increased with treatment duration in premenopausal women with breast cancer. Zoledronic acid 4 mg every 6 months effectively inhibited bone loss. Regular BMD measurements and initiation of concomitant bisphosphonate therapy on evidence of bone loss should be considered for patients undergoing endocrine therapy. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.02.7102","type":"journal-article","created":{"date-parts":[[2006,12,12]],"date-time":"2006-12-12T10:42:38Z","timestamp":1165920158000},"page":"820-828","source":"Crossref","is-referenced-by-count":277,"title":["Zoledronic Acid Prevents Cancer Treatment\u2013Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group"],"prefix":"10.1200","volume":"25","author":[{"given":"Michael F.X.","family":"Gnant","sequence":"first","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Mlineritsch","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Luschin-Ebengreuth","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grampp","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Kaessmann","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Schmid","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Menzel","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta Claudia","family":"Piswanger-Soelkner","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arik","family":"Galid","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Mittlboeck","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Hausmaninger","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimund","family":"Jakesz","sequence":"additional","affiliation":[{"name":"From the Departments of Surgery, Radiology, and Osteology; Core Unit for Medical Statistics and Informatics; and Division of Special Gynecology, General Hospital, Medical University of Vienna, Vienna; Departments of Internal Medicine III, and Nuclear Medicine and Endocrinology, Breast Center Salzburg, Paracelsus Private Medical University Salzburg, Salzburg; Department of Gynecology and Obstetrics; Department of Internal Medicine, Division of Oncology; and Department of Internal Medicine, Division of..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11745"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032312"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 23:87,2004,  (suppl, abstr 847)","DOI":"10.1200\/jco.2004.22.90140.847"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Jakesz R, Kaufmann M, Gnant M, et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88:S7,2004,  (suppl 1, abstr 2)","DOI":"10.1016\/S0960-9776(05)80118-3"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-2-126"},{"key":"R8","unstructured":"Emens LA, Davidson NE: Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 9:486S,2003-494S,  (suppl)"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(03)00392-7"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg119"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.112"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.064"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3817"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.3694"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1341"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.955"},{"key":"R17","unstructured":"Gasser JA, Green JR, Bhatnagar AS, et al: Intravenous administration of zoledronic acid offers long-term protection against bone loss in rats induced as a consequence of estrogen deprivation. Breast Cancer Res Treat 76:S78,2002,  (suppl 1, abstr 274)"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Brufsky A, Harker W, Beck J, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 23:12s,2005,  (suppl, abstr 533)","DOI":"10.1200\/jco.2005.23.16_suppl.533"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95"},{"key":"R21","unstructured":"Howell A: Effect of anastrozole on bone mineral density: 2-year results of the \u2018Arimidex\u2019 (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 82:S27,2003,  (suppl 1, abstr 129)"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601508"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.10.1108"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Hallberg I, Rosenqvist AM, Kartous L, et al: Health-related quality of life after osteoporotic fractures. Osteoporos Int 15:834,2004-841,","DOI":"10.1007\/s00198-004-1622-5"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Legroux-Gerot I, Lormeau C, Boutry N, et al: Long-term follow-up of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Clin Rheumatol 23:310,2004-317,","DOI":"10.1007\/s10067-004-0914-7"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Delmas PD, Li Z, Cooper C: Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330,2004-337,","DOI":"10.1359\/JBMR.0301228"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2003.12.022"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1385\/JCD:7:3:255"},{"key":"R29","unstructured":"Brufsky A, Harker G, Beck T, et al: Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial. Breast Cancer Res Treat 88:S233,2004,  (suppl 1, abstr 6038)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.02.7102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:15:28Z","timestamp":1653513328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.02.7102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,3,1]]}},"alternative-id":["10.1200\/JCO.2005.02.7102"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.02.7102","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}